Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-03: evorpacept plus pembrolizumab in advanced head and neck squamous cell carcinoma
2023-508340-22-00Phase 2Completed
- Sponsor
- ALX Oncology
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing evorpacept + pembrolizumab with pembrolizumab monotherapy (2 arms). Primary endpoint: Objective response rate. Started Apr 2024; status: completed.
02
Drugs
evorpaceptpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-508340-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508340-22-00.